ipamorelin cjc-1295 CJC 1295 No Dac (5mg) + (10mg) Blend CJC-1295 (Mod GRF 1-29) &

Evaluation and Treatment of Adult Growth Hormone Deficiency: An Endocrine Society Clinical Practice Guideline

Educational use only This page is an educational research reference, not medical advice or a treatment plan

effects diminish within 2-4 weeks of continuous use Ipamorelin: Maximum Selectivity Ipamorelin was designed specifically for selective GH release: GHS-R1a Selectivity: Activates only GH-releasing pathways at the receptor No Cortisol Effect: Does not stimulate ACTH or cortisol release No Prolactin Effect: Does not affect prolactin levels Minimal Appetite Effect: Unlike other GHRPs, does not significantly increase hunger No Cardiac Activity: Lacks Hexarelin's cardiac receptor effects No Desensitization: Effects maintain with continued use Key Trade-off: Hexarelin offers maximum acute GH release but with hormonal side effects and rapid desensitization

Cannabis is a plant that contains more than 100 biologically active chemical compounds called cannabinoids

Research has explored how elevated GH from CJC-1295 may support faster recovery from exercise and injury through the GH/IGF-1 pathway

But translating those acute hormonal changes into visible physical results takes time and consistency